Karus is a pharmaceutical company whose goal is to design, develop and partner innovative molecular-targeted, small molecule therapeutics to treat inflammation, immune disorders and cancer. The company's primary focus is the design and development of proprietary drugs that target epigenetic mechanisms and lipid kinase signalling.
The outstanding potency, efficacy and excellent tolerability of Karus's Histone Deacetylase Inhibitors (HDIs) represent a unique and innovative approach to the regulation of this important drug target, and brings the promise of new best-in-class therapies for the treatment of rheumatoid arthritis, psoriasis and cancer.
Karus's lipid kinase signalling program brings together a world-class research and development team that is using new insights to enable the design and development of pioneering, isoform-selective PI3-Kinase inhibitors to treat inflammatory disease and cancer.
Karus comprises an experienced scientific and commercial team with a highly successful track record in the biotechnology and pharmaceutical sector. This expertise has enabled the company to make efficient progress in its discovery and development programs.
Our expertise in small molecule drug design, combined with an underlying knowledge of target biology has allowed Karus to create
best-in-class therapeutics with blockbuster potential to treat major human diseases.
Simon Kerry, Chief Executive Officer
Karus Therapeutics Ltd
2 Venture Road
Southampton Science Park
Chilworth
Hampshire
SO16 7NP
United Kingdom